Riz--
I reread the August 2021 press release from Cytodyn regarding mTNBC. I don't think it was particularly well-written, and there are no hard survival numbers, just % increases in mPFS and mOS. But there is a minor correction worth noting as well as a couple encouraging items to add a little color your post.
First, the PR says there were 30 patients, not 28. 73% of the 30 exhibited a decrease in Circulating Tumor Cells (CTC) when given leronlimab. If that percentage holds up in later trials it is going to be huge! My California math tells me that 21 or 22 women responded to the drug. And if you were one of those 21 or 22 responders, "leronlimab was associated with a $400%-660% increase in mPFS/12-month PFS and a 570%-980% increase in mOS/12-month OS." So yeah, these kind of survival numbers should be a very big deal. And along with the unknown number of women who are currently disease free, we definitely should apply for and receive the BTD.
They also talk about the LifeTracDx test for CTCs, from Creatv MicroTech Inc, and suggest that it "appears to aid as a parallel diagnostic tool in identifying patients that respond to leronlimab." And the Big One is they can identify responders after a single dose! I would agree with Dr Pourhassan that this is "a truly remarkable finding." Anyone know if Creativ MicroTech is still around?
Some of you may remember the PR from 2021, but I confess I had forgotten these details. And the Cytodyn website only has press releases back to 2022, so it's a little frustrating it's not available there. A poster saved it and I found a link here or perhaps on ST, but I seem to have discarded the page. I did copy some of the relevant passages as I was preparing to write this, so here is some of the text verbatim from the PR:
"Decrease in Circulating Tumor Cells (CTC) as reported using the LifeTracDx™ test developed by Creatv MicroTech, Inc., after induction with leronlimab was associated with a 400%-660% increase in mPFS (modified Progression Free Survival)/12-month PFS (Progression Free Survival) and a 570%-980% increase in mOS (modified Overall Survival) /12-month OS (Overall Survival). Decreases in CTC after leronlimab induction were seen in 73% of the 30 patients in the study.
LifeTracDx™ appears to aid as a parallel diagnostic tool in identifying patients that respond to leronlimab. Data from these 30 patients are aligned with the premise that a majority of mTNBC patients respond to leronlimab if CTC reduction is observed following one leronlimab dose."
Dr Pourhassan goes on to say: “This report of results for 30 patients suggests that, with one blood test, we may be able to predict which mTNBC patients will respond well to leronlimab, which is a truly remarkable finding." Remarkable indeed!
If the mTNBC indication was a basketball game I'd say leronlimab is a slam dunk. Or a Curry three from the logo! Then I remember the severe covid trial... and take a big deep breath. But JL sounds really confident even as he keeps an appropriate even keel. "I expect the Company’s oncology efforts to accelerate in the coming months, with further announcements in both mTNBC and colorectal cancer.” Sounds like the ESMO abstract in May will be one of many press releases regarding leronlimab and cancer in the coming months.
I'm thinking perhaps a vacation is in the cards. Back to San Francisco for the NBA Finals? Anyone know what Greenland is like in the spring?
I reread the August 2021 press release from Cytodyn regarding mTNBC. I don't think it was particularly well-written, and there are no hard survival numbers, just % increases in mPFS and mOS. But there is a minor correction worth noting as well as a couple encouraging items to add a little color your post.
First, the PR says there were 30 patients, not 28. 73% of the 30 exhibited a decrease in Circulating Tumor Cells (CTC) when given leronlimab. If that percentage holds up in later trials it is going to be huge! My California math tells me that 21 or 22 women responded to the drug. And if you were one of those 21 or 22 responders, "leronlimab was associated with a $400%-660% increase in mPFS/12-month PFS and a 570%-980% increase in mOS/12-month OS." So yeah, these kind of survival numbers should be a very big deal. And along with the unknown number of women who are currently disease free, we definitely should apply for and receive the BTD.
They also talk about the LifeTracDx test for CTCs, from Creatv MicroTech Inc, and suggest that it "appears to aid as a parallel diagnostic tool in identifying patients that respond to leronlimab." And the Big One is they can identify responders after a single dose! I would agree with Dr Pourhassan that this is "a truly remarkable finding." Anyone know if Creativ MicroTech is still around?
Some of you may remember the PR from 2021, but I confess I had forgotten these details. And the Cytodyn website only has press releases back to 2022, so it's a little frustrating it's not available there. A poster saved it and I found a link here or perhaps on ST, but I seem to have discarded the page. I did copy some of the relevant passages as I was preparing to write this, so here is some of the text verbatim from the PR:
"Decrease in Circulating Tumor Cells (CTC) as reported using the LifeTracDx™ test developed by Creatv MicroTech, Inc., after induction with leronlimab was associated with a 400%-660% increase in mPFS (modified Progression Free Survival)/12-month PFS (Progression Free Survival) and a 570%-980% increase in mOS (modified Overall Survival) /12-month OS (Overall Survival). Decreases in CTC after leronlimab induction were seen in 73% of the 30 patients in the study.
LifeTracDx™ appears to aid as a parallel diagnostic tool in identifying patients that respond to leronlimab. Data from these 30 patients are aligned with the premise that a majority of mTNBC patients respond to leronlimab if CTC reduction is observed following one leronlimab dose."
Dr Pourhassan goes on to say: “This report of results for 30 patients suggests that, with one blood test, we may be able to predict which mTNBC patients will respond well to leronlimab, which is a truly remarkable finding." Remarkable indeed!
If the mTNBC indication was a basketball game I'd say leronlimab is a slam dunk. Or a Curry three from the logo! Then I remember the severe covid trial... and take a big deep breath. But JL sounds really confident even as he keeps an appropriate even keel. "I expect the Company’s oncology efforts to accelerate in the coming months, with further announcements in both mTNBC and colorectal cancer.” Sounds like the ESMO abstract in May will be one of many press releases regarding leronlimab and cancer in the coming months.
I'm thinking perhaps a vacation is in the cards. Back to San Francisco for the NBA Finals? Anyone know what Greenland is like in the spring?
13
